Sign up to save your podcasts
Or
Share Talquetamab Well Tolerated in Relapsed/Refractory MM
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Talquetamab Well Tolerated in Relapsed/Refractory MM
Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.
View all episodes
By HMP GlobalJesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.